BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Zapaq, Inc. Completes $6 Million Financing


10/19/2005 5:10:31 PM

WALTHAM, Mass. and OKLAHOMA CITY, March 19 /PRNewswire/ -- Zapaq, Inc., a drug discovery and development company, announced that it has obtained $6 million in private financing from two premier venture capital firms-Sanderling Ventures and Yamanouchi Venture Capital.

"This financing allows us to make significant advances toward the clinical development of a compound that could delay or even halt the progression of Alzheimer's Disease," said Zapaq President and CEO James Jenson, Ph.D.

The company's scientific founders, Jordan Tang, Ph.D., of the Oklahoma Medical Research Foundation and Arun Ghosh, Ph.D., of the University of Illinois, have made a series of groundbreaking discoveries about a family of enzymes (known as aspartic proteases) believed to play a key role in Alzheimer's. Zapaq is now building on that work to develop a drug that will block the progression of the disease.

"At Sanderling, we have been carefully observing scientific progress in the area of Alzheimer's Disease for 20 years," said Robert McNeil, Ph.D., a Managing Director of Sanderling Ventures who has also been named Chairman of Zapaq's Board of Directors. "With its unique technology and experience, Zapaq represents the first true opportunity to develop a therapy that will treat Alzheimer's at its source." Paul Grayson, a Director of Sanderling Ventures, will also join the Zapaq Board.

Zapaq is also using its work on aspartic proteases as a platform for discovering drugs to treat infectious and cardiovascular diseases.

The company previously received more than $1 million in seed financing from the Oklahoma Life Sciences Fund and the Institute for the Study of Aging, a biomedical venture philanthropy founded by the Estee Lauder Trust. "With the help of our initial investors and our new venture partners, Zapaq can now proceed with selecting and developing a compound suitable for testing in human clinical trials for Alzheimer's Disease," Jenson said.

About Zapaq:

Zapaq, Inc. is a privately held biopharmaceutical company focused on discovering and developing therapeutics that target aspartic proteases, a group of enzymes central to a variety of human diseases, including Alzheimer's. The company is headquartered in Waltham, MA and has research and development operations in Oklahoma City, OK.

Contact: James Jenson Zapaq, Inc. (781) 839-7237

Zapaq, Inc.

CONTACT: James Jenson of Zapaq, Inc., +1-781-839-7237



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES